Skip to main content

Correction to: The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia

The Original Article was published on 17 June 2020

Correction to: Journal of Hematology & Oncology (2020) 13:78 https://doi.org/10.1186/s13045-020-00909-y

The original article [1] contains an error in Fig. 6b for the image of western blot panels.

Fig. 6
figure6

LAMP5-AS1 could serve as a prognostic predictor of MLL leukemia. a Reanalysis of the GSE62190, GSE66917 and GSE67039 data sets with 419 patient samples classified into MLL leukemia and MLL-wt subtypes. LAMP5-AS1 expression presented the highest levels in MLL leukemia. (Mann–Whitney test, p < 0.001). b LAMP5-AS1 and MLL fusion protein levels in 7 paired MLL leukemia patients (initial diagnosis versus complete response, CR), and the MLL fusion protein levels were positively correlated with those of LAMP5-AS1 (CT) at preliminary diagnosis (Pearson r = -0.8817, p < 0.01). Relative expression (ΔCT) was used to quantify LAMP5-AS1 expression relative to a housekeeping gene (GAPDH). c ROC curve analysis showed that LAMP5-AS1 had high AUC values of 0.7572 (95% confidence interval (CI): 0.6625–0.8519) and 0.9280 (95% CI: 0.8904–0.9620, p < 0.001) in the GSE62190, GSE66917 and GSE67039 data sets (n = 35 for MLL leukemia and n = 384 for MLL-wt) and validation set (n = 58 for MLL and n = 163 for MLL-wt), respectively, with considerably significant sensitivity (sen.) and specificity (spe.) at the optimal cutoff point calculated by Youden’s index. d The 5-year leukemia-free survival of patients with a high expression level of LAMP5-AS1 is less than that of patients with a low LAMP5-AS1 level in MLL leukemia (n = 200, p < 0.01). e A working model proposed for the specific activation of DOT1L/H3K79 methyltransferase by LAMP5-AS1 binding to regulate MLL leukemia self-renewal

The correct presentation of Fig. 6b is shown below.

Reference

  1. 1.

    Wang W-T, et al. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia. J Hematol Oncol. 2020;13:78. https://doi.org/10.1186/s13045-020-00909-y.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yu-Meng Sun.

Additional information

Publisher's Note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, WT., Chen, TQ., Zeng, ZC. et al. Correction to: The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia. J Hematol Oncol 14, 42 (2021). https://doi.org/10.1186/s13045-020-00967-2

Download citation

\